Back to top
more

Xeris Pharmaceuticals (XERS)

(Real Time Quote from BATS)

$5.56 USD

5.56
2,074,150

+0.18 (3.35%)

Updated Aug 4, 2025 03:55 PM ET

After-Market: $5.57 +0.01 (0.18%) 4:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last?

by Zacks Equity Research

Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xeris Biopharma (XERS) delivered earnings and revenue surprises of 14.29% and 4.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates

by Zacks Equity Research

Corcept (CORT) delivered earnings and revenue surprises of 0% and 11.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?

by Zacks Equity Research

Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Here's What Key Metrics Tell Us About Xeris Biopharma (XERS) Q4 Earnings

by Zacks Equity Research

Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Xeris Biopharma (XERS) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Xeris Biopharma (XERS) delivered earnings and revenue surprises of 57.14% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sea Limited to Post Q4 Earnings: What's in Store for the Stock?

by Zacks Equity Research

SE's fourth-quarter performance is likely to have benefited from strong Shopee and SeaMoney growth. Competition and FX volatility are expected to have hurt profitability.

Zacks Equity Research

Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Verrica Pharmaceuticals (VRCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aclaris (ACRS) delivered earnings and revenue surprises of 68.75% and 313.05%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Xeris Biopharma (XERS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Xeris Biopharma (XERS) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

Xeris Biopharma (XERS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xeris Biopharma (XERS) delivered earnings and revenue surprises of 33.33% and 5.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of -20.83% and 10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?

by Zacks Equity Research

Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xeris Biopharma (XERS) delivered earnings and revenue surprises of 9.09% and 2.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q2 Earnings Expected to Decline

by Zacks Equity Research

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Will Xeris Biopharma (XERS) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Xeris Biopharma (XERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 52.63% and 52.56%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xeris Biopharma (XERS) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

Is it a good or bad thing when a stock experiences a golden cross technical event?

Zacks Equity Research

Xeris Biopharma (XERS) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xeris Biopharma (XERS) delivered earnings and revenue surprises of -16.67% and 2.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?

by Zacks Equity Research

MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Xeris Biopharma (XERS) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Xeris Biopharma (XERS) delivered earnings and revenue surprises of -11.11% and 2.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -50% and 12.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Xeris (XERS) Might Surprise This Earnings Season

by Zacks Equity Research

Xeris (XERS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza

by Zacks Equity Research

Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.